Beta-galactosidase glycosphingolipid (BioLineRx)

N/A

Report date: 2024/06/03 17:58:51
NME

Base Information

Drug NameBeta-galactosidase glycosphingolipid (BioLineRx)
Drug Alias NameGSL-alpha-GALGlycosphingolipid beta-galactosidase immunotherapy (BioLineRx)Alpha-gal glycosphingolipids (BioLineRx)AGI-134
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytotoxic T lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAgalimmune Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAgalimmune Ltd
Inactive CompaniesUniversity Of Massachusetts Medical School
Active IndicationsSolid tumours
Inactive IndicationsNeoplasm MetastasisMelanoma

Other Information

ATC CodeN/A
Related LinksN/A